AR and cancer: However, in certain cases, despite androgen deprivation therapy (ADT), cancer could progress to Castration-Resistant Prostate Cancer (CRPC) due to: AR gene amplification, AR mutations and splice variants, intratumoral androgen synthesis or activation of AR by other signaling pathways.